Highlands Oncology Group

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Bladder cancer4 trials
• Colorectal cancer4 trials
• Melanoma4 trials
• Head and neck cancer3 trials
• Kidney cancer3 trials
• Ovarian cancer3 trials
• Cervical cancer2 trials
• Gastric and oesophageal cancer2 trials
• Pancreatic cancer2 trials
• Endometrial cancer1 trial
• Liver and biliary tract cancer1 trial
• and 3 more

Phase

• Phase 15 trials
• Phase 34 trials
• Phase 1/22 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting7 trials
• Terminated4 trials
• Completed3 trials

Lead sponsor

• Pfizer9 trials
• Adcendo ApS1 trial
• BostonGene1 trial
• Hoffmann-La Roche1 trial
• Laekna Limited1 trial
• and 1 more

Running trials

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  NCT07226999· Phase 2/3· Pfizer· Source

• Recruiting

  ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

  NCT06597721· Phase 1· Adcendo ApS· Source

  Contact: Sherri Paxton

• Recruiting

  BostonGene and Exigent Genomic INsight Study

  NCT06272864· BostonGene· Source

  Contact: Adam Torres

• Recruiting

  A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  NCT04389632· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Head and neck cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Terminated

  A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

  NCT06704724· Phase 1· Pfizer· Source

• Terminated

  A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

  NCT06580938· Phase 1· Pfizer· Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Phase 1· Pfizer· Source

• Completed

  Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

  NCT04374630· Phase 2· Laekna Limited· Source

• Terminated

  A Study of PF-06873600 in People With Cancer

  NCT03519178· Phase 1/2· Pfizer· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source